Decoy Therapeutics Secures $3.85 Million in Warrant Inducement Deal to Further Antiviral Innovations

Decoy Therapeutics Secures $3.85 Million in Warrant Inducement Deal

On September 22, 2026, Decoy Therapeutics, Inc., a notable player in the biotechnology sector, publicly announced a strategic financial maneuver designed to bolster its innovative antiviral research. The company, which operates under the NASDAQ ticker DCOY, aims to raise approximately $3.85 million through a warrant inducement arrangement that targets existing institutional investors. This endeavor focuses on the exercise of Series B Milestone Warrants.

Decoy Therapeutics specializes in developing Designable Multi-Antivirals (D-MAVs™), a groundbreaking class of antiviral drugs engineered to target conserved viral mechanisms across multiple virus families. These innovations are crucial for addressing significant public health challenges posed by various viral diseases.

Details of the Warrant Transaction

In this transaction, existing investors will exercise 1,184,434 Series B Milestone Warrants at a reduced exercise price of $3.25 per share, considerably lower than previous pricing levels. As part of the agreement, the exercise price of other outstanding warrants, specifically Series A and C Milestone Warrants, will also be adjusted from $5.91 to the new price of $3.25. This altered pricing aims to incentivize immediate participation from investors, enabling Decoy to secure essential funds swiftly.

As a result of exercising these warrants, Decoy is expected to receive gross proceeds close to $3.85 million, which will be dedicated to advancing their working capital and broader corporate initiatives.

In exchange for their full participation, the investors will receive new unregistered warrants enabling them to purchase additional shares of common stock. The new warrants will allow investors to acquire up to 2,368,868 shares at the same $3.25 price, with an expiration of five years from the initial exercise date, subject to shareholder approval.

Future Plans and Goals

This strategic financial move is part of Decoy Therapeutics’ broader effort to solidify its position in the competitive biotechnology landscape. The funds generated from this transaction are intended to expedite the company's ongoing research and development activities, particularly in creating antiviral solutions that can adapt to evolving viral threats.

Decoy’s proprietary IMP³ACT™ platform, which integrates artificial intelligence with rapid peptide synthesis, underpins its D-MAVs technology. This unique approach allows for swift transitions from concept to clinical applications, positioning Decoy at the forefront of innovation in viral disease prevention and treatment.

Conclusion

As Decoy Therapeutics embarks on this financial venture, it reflects their commitment to pioneering antiviral solutions. The immediate influx of capital through this warrant inducement highlights investor confidence in Decoy's potential to transform the fight against viral diseases. The transaction, set to close by September 23, 2026, remains contingent on customary closing conditions being satisfied, showcasing the proactive nature of the company in securing its future. As Decoy Therapeutics moves forward, the biotechnology community watches closely, anticipating further advancements in antiviral therapies that could substantially benefit public health.